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Keith M. Sullivan,1 Paolo Muraro,2 Alan Tyndall3Considerable advances have been made in our understanding of the immunobiology of autoimmune disease
and its treatment with hematopoietic cell transplantation (HCT). In autoimmune disorders, the reconsti-
tuted immune system following lymphoablation and autologous HCT yields qualitative changes in immune
defects and modifications in adaptive immune responses. Seminal experiments in animals demonstrated
that allogeneic or autologous HCT could prevent progression or reverse organ damage from inherited
(genetic) or acquired (antigen induced) autoimmune diseases. Convincing animal and clinical data now
show that after HCT, the immune system is normalized and ‘‘reset’’. Following autologous transplantation,
this resetting occurs via repertoire replacement. It is currently being studied whether and to what extent
suppression of inflammation after HCT is due to reregulation of function or due to the eradication of disease
associated Tand/or B cell populations. There are now a number of published clinical reports with sufficient
follow-up for determinations of safety and efficacy of HCT for autoimmune diseases. On behalf of colleagues
in the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow
Transplantation (EBMT), we review the experience with more than 1000 transplants for autoimmune disease
in Europe along with the three major multinational randomized trials in for systemic sclerosis (SSc, the ASTIS
study), multiple sclerosis (MS, the ASTIMS study), and Crohn’s disease (CD, the ASTIC study). Completed
phase II studies in the USA of transplantation for severe SSc, SLE and MS yield promising results. For indi-
viduals with SSc, there is dramatic improvement/resolution of dermal fibrosis and stabilization/improvement
of pulmonary dysfunction reported up to 8 years after lymphoablative conditioning and autologous HCT.
Currently, randomized phase III studies are recruiting subjects in the USA with SSc, MS and CD. In addition,
9 other phase I and II trials in the USA are recruiting patients with autoimmune diseases for nonmyeloablative
transplants from allogeneic stem cell donors. Research opportunities abound, but recruitment challenges
restrict study entry due to organ impairment from advanced autoimmune disease or insurance denial of cov-
erage for HCT. However, within several NIH sponsored trials there are ongoing immunologic, genomic and
mechanistic studies to further understand the molecular mechanisms of autoimmunity, immune regulation
and response to treatment. These clinical trials will provide basic scientists with insight into immunoregu-
latory pathways and clinicians with a context to weigh the progress and evidence in this evolving treatment
for autoimmune diseases.
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Ikehara, van Bekkum and their colleagues [1,2]. Still,
a decade elapsed between the preclinical studies and
human trials. Appreciation of the potential for cure
of autoimmune disease was bolstered by illustrative
experiments in nature wherein patients with coinci-
dent autoimmune disease and hematologic malig-
nancy or AA remained in long-term remission of
both diseases after allogeneic transplantation [3].
As predicted by Thomas, a variety of problems and
opportunities encompassed these first clinical trans-
lations [4]. Now, with initial trials in several autoim-
mune diseases published with sufficient follow-up
for determinations of safety and efficacy, it is oppor-
tune to review the biology and results to date and
glimpse from both sides of the Atlantic into the
future of transplantation for autoimmune diseases.RESETTING THE IMMUNE SYSTEM TO
CONTROL AUTOIMMUNE DISEASE:
PRECLINICAL AND CLINICALTRANSPLANT
EXPERIENCE
Current concepts on the pathogenesis of autoim-
mune disorders attribute a crucial role to T and B cells
inappropriately recognizing self antigens and initiating
a cell-mediated or humoral reaction, or both, resulting
in inflammatory tissue and vascular damage [5]. Treat-
ing autoimmune disease with antigen-specific toleriza-
tion has been an ambitious, but largely elusive, goal
and both pharmaceutical and academic-driven drug
development efforts have targeted shared effector or
regulatory pathways with immunosuppressive/modu-
latory compounds.
Autologous hematopoietic cell transplantation
(HCT) is being evaluated as treatment for severe forms
of immune-mediated disorders including multiple
sclerosis (MS), systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), and rheumatoid arthritis
(RA) or juvenile idiopathic arthritis (JIA). The goal
of this therapy is to induce medication-free remission
from disease activity by correcting the immune aberra-
tions that promote the attack against self tissue
(‘‘immune repair’’).
Animal Models
Collagen-induced arthritis (CIA) and experimental
autoimmune encephalomyelitis (EAE) are examples of
antigen-induced autoimmune diseases, and serve as
models for human RA and MS, respectively. Data in
both disease models suggest that tolerance induced
by autologous HCT can prevent autoimmunity even
after antigenic reencounter. In van Bekkum’s studies
of bone marrow transplantation (BMT) in experimen-
tal models, amelioration of autoimmune disease was
observed not only after syngeneic but also after autol-ogous or pseudoautologous BMT (reviewed in [6]).
Remarkably, arthritic rats treated with syngeneic
BMT did not relapse with CIA even after being reim-
munized with the antigen [2]. Syngeneic transplanta-
tion also conferred protection from disease relapse in
EAE [7]. To explain these observations wemust postu-
late the induction of protective changes of the immune
system not linked to a correction of an underlying stem
cell defect. We have recently observed that BMT
applied to mice in the late phase of EAE development
resulted in different clinical outcomes. Numbers of
activated macrophage/microglial cells were signifi-
cantly greater in mice that progressed, and tracking
of green fluorescent protein-transduced BM cells
showed the endogenous origin of the activated micro-
glia [8]. Therefore, tissue-specific factors such as the
persistence of local inflammatory cell types may influ-
ence the clinical outcome independent of the effects
of BMT on the peripheral adaptive immune system
(T and B lymphocytes).
Not Just Immune Suppression
Early studies on immune reconstitution following
autologous transplant for both autoimmune diseases
and cancer showed a profound lymphopenia in the first
year after transplantation. The cytopenia was observed
to affect the lymphocyte subsets differently, the kinet-
ics of reconstitution likely depending on different tim-
ing of recovery for each cell type. Whereas B cells,
natural killer (NK) cells, and CD81 T cells display
a rapid and complete reconstitution to pretransplanta-
tion levels, the recovery of CD41 T cells has con-
sistently been observed to be delayed, and often
incomplete. By extending longitudinal follow-up of
patients, recent studies have shown a recovery of the
number of CD41 T cells after a 2-year follow-up in
young adults treated for MS [9] and RA [10], and after
12 months in children with JIA [11]. The observation
that quantitative recovery of lymphocytes was not
correlated to inflammatory activity or disease relapse
revealed that numeric immune deficit is an insufficient
explanation for a prolonged absence of autoimmune
disease activity after autologous HCT.
Immune Resetting via Repertoire Replacement
The rationale for using autologous HCT in auto-
immune disease is to purge the existing immune sys-
tem and regenerate a new and healthy repertoire of
immune cells. However, the notion of an immune
‘‘resetting’’ remained conjectural until Muraro et al.
[9] demonstrated the regeneration of a new, naı¨ve T
cell repertoire emerging from the thymus of patients
with MS who had been treated with myeloablative
(MA) conditioning and autologous HCT. In this
study, a detailed analysis of T cell receptor repertoire
showed the regeneration of a different and more
S50 Biol Blood Marrow Transplant 16:S48-S56, 2010K. M. Sullivan et al.diverse TCR repertoire posttransplant. Thymic
reactivation, expansion of naı¨ve T cells following auto-
grafting, and improved repertoire diversity were sub-
sequently also demonstrated in individuals with SLE
[12]. Important lessons also come from studies on an-
tibody responses to foreign antigens such as after vac-
cination or revaccination preceding or following
autologous transplant. In a recent study, immunoabla-
tive conditioning and autologous HCT eliminated im-
munologic memory for a neoantigen given after the
graft harvest, and diminished, although did not com-
pletely eliminate, the immunologicmemory for a recall
antigen boosted before harvest following nonrigorous
T cell depletion of the autograft [13]. Serologic evi-
dence of attenuation of immunologicmemory suggests
that the B cell compartment, until now less extensively
investigated, may also undergo a renewal through
autologous HCT.Immune Resetting via Restoration of Immune
Regulation
Potentially pathogenic autoimmune responses are
generated not infrequently and failure of tolerance
toward self may also require the failure of protective
immunoregulatory mechanisms. Autoimmune disease
can therefore be regarded as the final outcome of a
series of events that likely include not only a genetic
susceptibility, but also the failure of the checkpoints
available to prevent autoimmunity following exposure
to environmental challenges, such as infections (Fig-
ure 1). It is reasonable to postulate that the normaliza-
tion of immune regulatory mechanisms could play
a role in the suppression of autoimmunity following
autologous HCT. The CD41 CD251 expressing the
forkhead transcription factor 3 (FoxP3) cells are potenttnemnorivnE
Genes
• dnanegohtaP
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(+hormones)
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Figure 1. Both genetic and environmental factors play a role in the de-
velopment of autoimmune disease. Development of autoimmune dis-
ease in adulthood suggests that multiple immunizing events are
required to break immune tolerance. It is proposed that autologous
HCT, by ‘‘resetting’’ the immunological memory, may return the individ-
ual’s immune system to a premorbid state, resulting in a prolonged clin-
ical remission.suppressors of immune responses, which are generated
in the thymus both in rodents [14] and in humans [15].
CD25high FoxP31 CD41 T cells were reported to be
more resistant to irradiation than effector cells and
mediated the amelioration of experimental graft-
versus-host disease (GVHD) [16]. In EAE rats, there
was an increase ofCD41CD251Tcells after syngeneic
BMT and this was seen in connection with attenuation
of active disease and protection from induction of re-
lapses [17]. Longitudinal enumeration of CD41CD25
high T cells in children with JIA, studied following au-
tologous HCT, showed recovery of the pretreatment
frequency at 6 months posttransplant and a continued
increase for the remaining 12-month follow-up. Their
frequency correlated directly with clinical remission.
Therefore, reinstallation of immune regulation could
be involved in long-term tolerance posttransplant.AUTOLOGOUS HCT FOR SEVERE
AUTOIMMUNE DISEASE: THE EXPERIENCE
IN EUROPE
The Hypothesis
As detailed before, autoimmune diseases result
from failure of an organism to recognize its own parts
as ‘‘self,’’ thereby producing an autoaggressive re-
sponse. The components of this response are as pleio-
morphic as the immune system itself, ranging from
cells and molecules of the innate immune system
such as dendritic cells (DCs) and NK cells to the
tightly regulated members of the adaptive immune
system. Targeting these individual components with
chemical or biological agents has been extremely effec-
tive in controlling symptoms in many patients, but still
some patients do not respond sufficiently and may lose
life or vital organ function or suffer severe toxicity
from treatment. Also, no therapy to date has induced
long-term drug-free remission in any autoimmune
disorder.
Based on animal models and anecdotal experience
of HCT patients with coincidental autoimmune dis-
eases mentioned earlier, it was proposed that by erad-
icating the whole immune system, tolerance could be
reestablished during the immune reconstitution that
follows lymphoablation. As in other HCT protocols,
it was hoped that the early increased transplant-related
toxicity, compared with standard of care, would be off-
set by a later increased disease-free survival (DFS).The Plan
Colleagues from hematology, rheumatology, im-
munology, neurology, and gastroenterology sat to-
gether 14 years ago in Basel [18] and Seattle [19] to
work out a structured research agenda that had as its
mission statement 2 main objectives: (1) to show
Biol Blood Marrow Transplant 16:S48-S56, 2010 S51Hematopoietic Cell Transplantation for Autoimmune Diseasethrough prospective, randomized controlled trials
(RCTs) whether autologous HCT offered a durable
and significant improved quality of life for patients suf-
fering from severe autoimmune disease; and (2) to
study immune reconstitution in such patients to under-
stand better the cellular and molecular mechanisms
involved.
Autologous HCTwas initially chosen because of its
lesser toxicity comparedwith allogeneicHCT.A limited
numberof protocolswereproposed to allowcomparison
ofmore aggressiveMAand reduced intensity condition-
ing (RIC) regimens. At the time, it was not known
whether complete eradication of all autoreactive im-
mune competent cells was required, or rather simply
an autoimmune ‘‘debulking’’ to allow natural immune
regulation to be reestablished. A gratifying international
scientific collaboration became established, which re-
mains today.
The Early Results
From the first case report of a 45-year-old female
with untreatable pulmonary hypertension and SSc
[20], through the small case series and then phase
I/II studies, there was a strong impression that autolo-
gous HCT influenced the natural history of several
autoimmune disorders, including SSc, MS, RA, JIA,
SLE, and Crohn’s Disease (CD). In addition, impres-
sive positive results were also seen for less common
disorders, such as chronic inflammatory demyelinating
polyneuropathy (CIDP) and various vasculitides.
A first mega analysis on 473 patients from the
EBMT in 2005 showed that 11% has died, either
from treatment-related toxicity (TRM) (7%) or disease
progression (5%), adjusted to an average 3 year follow-
up [21]. Of the patients evaluable for response (n 5
299), 81% responded and this was sustained in 71%.
Not reported then, but subsequently demonstrated,
were many of these responders with apparent long-
term, drug-free remission demonstrating tissue re-
modeling. Conditioning regimens were classified as
low, intermediate, or high intensity, and although re-
sponses were better in the high-intensity regimes, the
associated increased toxicity with these initial trials
was considered unacceptably high. Subsequent proto-
col designs for the prospective RCTs in Europe were
based on the intermediate intensity regimens, mostly
consisting of mobilization with cyclophosphamide
(Cy) and granulocyte-colony stimulating factor
(G-CSF) followed by Cy (or BEAM) and antithymo-
cyte globulin (ATG) plus or minus CD341 cell selec-
tion. Randomized trials have been designed for SSc,
MS, CD, RA, and CIDP.
Events Along the Way
InDecember1993, a landmarkarticlewas published
showing a dramatic and hitherto unseen response in20RApatients over 8weeks to the tumor necrosis factor
(TNF)-ablocking agent, the chimericmonoclonal anti-
body (mAb), infliximab [22]. Toxicity was modest and
this experience opened an era of biopharmaceuticals,
first revolutionizing the treatment of RA, then rapidly
spreading to CD, MS, and now becoming established
or investigational therapy inmost autoimmune diseases.
Although none of these offer a ‘‘cure,’’ the toxicity
is rather low and the trials are supported by the phar-
maceutical industry. This had an impact on the re-
cruitment of patients with autoimmune disease onto
transplant trials, because whereas best results with
HCT are seen in early, reversible autoimmune disease,
such patients are also suitable for less toxic biopharma-
ceuticals. Of note, so far an effective disease modifying
agent for SSc is not available for this highlymorbid and
mortal disorder.
In 2001, the European Parliament enacted the Eu-
ropean Union’s Clinical Trials Directive 2001/20/EC,
which has had a profound effect on clinical trials in
Europe. This is a lengthy document specifying all as-
pects of the clinical trials process, and has proved com-
plicated for investigator-initiated trials such as studies
of HCT for autoimmune disease, which are often uni-
versity based and extend across national borders. This
regulatory burden has hindered the clinical trialist,
especially as it relates to professional indemnity.Randomized Clinical Trials
Table 1 presents the current status of RCTs in
Europe as of August 2009. The Autologous Stem
cell Transplantation International Scleroderma Trial
(ASTIS) has almost completed enrollment, and al-
though deaths have occurred in both arms, the
independent safety committee has adjudicated that no
unexpected toxicity occurred. The Autologous Stem
cell Transplantation International Rheumatoid Arthri-
tis trial (ASTIRA) never started because of a plethora of
biopharmaceutical agents for RA including anti
TNF-a, interleukin (IL)-1 , IL-6, and costimulation
blockade.Impact of HCTon Autoimmune Disease
SSC
Some patients have achieved complete remission
(CR) including unexpected and dramatic clinical and
biopsy regression of dermal fibrosis as well as normal-
ization of the microvasculature [23].
SLE
In a small series of patients, clinical CRs as well as
loss of autoantibody (antinuclear antibody) have been
described, suggesting a true resetting of autoimmu-
nity. This has been attributed to eradication of long
lived plasma cells.
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Both clinical improvement and loss of active MRI
lesions have been described [24]. These improvements
persist despite return of a normal immune repertoire.
The Future
Since the 2005 analysis, additional patients have
been registered in the EBMT/EULAR database (sta-
tus update March 2009, courtesy of D Farge): total
n 51031 consisting of MS n 5 379 , SSc n 5 207,
SLE n 5 92, RA n 5 88, JIA n 5 70, ITP n 5 23,
CD n 5 23. A recent analysis of the EBMT/EULAR
database (D. Farge, personal communication) suggests
a reduction in TRM attributable to more precise pa-
tient selection. However, some long-term follow-up
data are missing, and one must assume that HCT
will always be associated with some degree of TRM.
The EBMT, EULAR, and the other learned societies
are committed to completing these prospective RCTs
and, if positive, developing more focused future proto-
cols including mechanistic side studies to exploit the
effectiveness and reduce the toxicity of HCT in auto-
immune disorders. In the meantime, members of the
Autoimmune Disease Working Party of the EBMT
‘‘consider it noncontributory to transplant patients
with autoimmune disease outside the context of an
approved, prospective RCT.’’AUTOGRAFTS AND ALLOGRAFTS FOR
AUTOIMMUNE DISEASE: CHALLENGES AND
OPPORTUNITIES IN CROSSDISCIPLINARY
RESEARCH IN THE UNITED STATES
Transplant Activity in the United States
Initial published experience focused on autologous
HCT for 3 autoimmune disorders: severe diffuse
scleroderma with internal organ involvement (SSc),
SLE, andMS. Among 34 patients with life-threatening
SSc followed up to 8 years after autologous transplant,
stabilization/improvement of pulmonary disease and
significant improvement in dermal sclerosis and func-
tioningwere observed [25]. Figure 2 depicts these trans-
plant outcomes. This experience formed the basis of
a phase III randomized comparison of intensive immu-
nosuppression with 12 monthly pulses of i.v. Cy (750
mg/m2) versus immunoablation followed by CD341
selected autologous HCT in the SCOT (Scleroderma:
Cyclophosphamide Or Transplantation) protocol
(http://www.sclerodermatrial.org).
Encouraging results have also been reported in 50
patients with SLE followed to 7.5 years after autograft-
ing [26]. A subsequent phase III LIST (Lupus Immu-
nosuppressive/immunomodulatory therapy or Stem
cell Transplant) trial will be discussed below. In addi-
tion, 2 phase II U.S. trials in MS with 4-year follow-up
Figure 2. Improvements in serial Rodnan skin score (A), Health Assessment Questionnaire (B), Forced Vital Capacity, FVC (C) and Diffusion Capacity,
DLCO (D) following immunoablation and autologous HCT. Gray solid lines depict individual patient parameters. Solid black lines are mean values and
dashed lines represent the generalized estimating equation (GEE) for repeated measures. Mean Rodnan scores (0 is normal, 51 is maximal skin hardening
throughout the body) decreased over time (P\.001). Improvements in mean Health Assessment Scores (0 is normal) were also significant (P\.001).
The mean FVC values improved over time (P5.01), whereas the mean DLCO did not change significantly (P5.5). This research was originally published
in Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe
systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood, 2007;110:1386-1396. Copyright the American Society of Hematology.
Biol Blood Marrow Transplant 16:S48-S56, 2010 S53Hematopoietic Cell Transplantation for Autoimmune Diseasehave been reported with apparent reduction in MS
episodes [27,28].
Table 2 lists currently open HCT trials for adults
with autoimmune disorders as registered with Clinical-
Trials.gov. Six major diseases each with 2 to 6 accruing
studies arepresented.Of these26 trials, 15are autologous
and 11 allogeneic transplant studies. Only 5 of the 26
are randomized trials and only 4 are NIH supported.
Cross Disciplinary Considerations
For patients with severe SSc, comorbid organ
impairment is common; for those with MS, timing
of HCT is an issue; and for individuals with SLE,
a host of conventional treatments are competing op-
tions. With experience gained in autologous HCT
for autoimmune disease, and with considerable allo-
graft experience with RIC regimens for hematologic
malignancies, allogeneic transplant regimens are be-
ing investigated for autoimmune disorders [29]. Col-
laboration across disciplines promotes recruitment
of patients onto HCT trials despite restricted fund-
ing by insurers that remains a significant issue, as
predicted at the beginning of this clinical research
[19]. What was less clear a decade ago was the re-
lentless growth in regulatory steps in protocol
development. For example, for 16 trials of the East-ern Cooperative Oncology Group, some 481 distinct
processes were required to activate a protocol con-
suming a median of 808 days effort from study con-
cept to enrollment [30]. This delay is not unique to
oncology. The LIST study was an NIH supported
randomized transplant trial in SLE [31]. It was never
activated because of delays in protocol development.
Physician Barriers to Protocol Recruitment
Despite formation of cooperative and community
research groups, annual enrollment onto oncology
trials in the United States remains stuck at 3% of all
newly diagnosed adults with cancer [32]. Factors cited
by physicians as road blocks to patient recruitment
include extra uncompensated time required to enroll
subjects, regulatory paperwork, and insurance over-
load. It has recently been estimated that $31 billion rep-
resents the collective cost to U.S. physician practices
for time spent on interactions with insurers for
approval of nonprotocol tests and treatments [33]. As
the authors of the study note, this cost to interact
with health plans is equal to 6.9% of all U.S. expendi-
tures for physician and clinical services.Health insurers
may further restrict protocol recruitment by denial or
delay of coverage for treatment on a study. Because of
uncertainty about insurer reimbursement for clinical
Table 2. Recruiting Clinical Trials of HCT for Adults with Autoimmune Disease (Listed on ClinicalTrials.gov as of 8/30/09)
Study Autologous Allogeneic Phase Randomized Location # Patients Needed NIH Sponsored Start Date
Scleroderma (systemic sclerosis)
1 + II + USA 60 Sep 2005
2 MSD/MUD II USA 20 Aug 2006
3 MSD/CBD II USA 10 NCI May 2005
4 + III + USA 113 NIAID Jun 2005
5 MSC II China 20 Aug 2009
6 MSD I USA 12 Aug 2007
Systemic lupus erythematosus
1 MSD I USA 15 NHLBI Jun 2004
2 MSD I USA 10 Jul 2004
3 MSD I USA 12 Aug 2007
4 MSD II USA 20 Jan 2003
5 MSC I/II China 20 Mar 2007
6 + I Germany 30 Aug 2008
Multiple sclerosis
1 + II USA 30 NIAID Jul 2006
2 MSD II USA 20 Jan 2003
3 + III + USA, Canada, Brazil 110 Jan 2006
Rheumatoid arthritis
1 + I USA 10 Jun 1997
2 MSD I USA 20 Sep 2002
Inflammatory bowel disease
1 + II + USA 110 Apr 2005
2 + II USA 25 Apr 2001
3 + III + EBMT 48 Jun 2006
Type I diabetes mellitus
1 + I/II Brazil 24 Dec 2003
2 + I UK 18 Nov 2008
3 + I/II China 200 Mar 2006
4 + I/II China 30 Jan 2008
5 + I/II Philippines 30 Nov 2007
6 + II China 30 Feb 2008
CBD indicates cord blood donor; EBMT, European Bone Marrow Transplant Group; HCT, hematopoietic cell transplant; MSC, mesenchymal stem cells;
MSD, HLA matched sibling donor; MUD, matched unrelated donor; NCI, National Cancer Institute; NHLBI, National Heart, Lung Blood Institute;
NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health.
S54 Biol Blood Marrow Transplant 16:S48-S56, 2010K. M. Sullivan et al.trials, 26 states have enacted legislation requiring all
third-party payers to cover participation in cancer
clinical trials (21 states) or in trials for life-threatening
diseases (5 states). Laws require that trials be approved
by the NIH, NIH Cooperative Group or Center,
FDA, or the Departments of Defense or Veterans Af-
fairs (http://www.cancer.gov/clinialtrials/ctlaws-home).
Unfortunately, only 5 of the 50 states mandate insurers
to support clinical trials for life-threatening, nonmalig-
nant diseases.
Patient Barriers to Protocol Recruitment
Although adults in America are either very willing
(32% of those surveyed) or inclined (38%) to partici-
pate in a clinical trial, most do not [34]. Fewer than
1% of the U.S. population enrolls each year in approx-
imately 80,000 open clinical trials. When surveyed,
major barriers to enrollment were not patient attitude;
rather, the unavailability of an appropriate trial, dis-
qualification because of comorbidities, and concerns
about transportation or insurance coverage were the
major impediments [34].
Insurance Barriers to Protocol Recruitment
Unique among the wealthy nations, the United
States has tens of millions of citizens without anyhealth care coverage from private insurer or third-
party agency. The national debate on health care
for the uninsured continues, but it remains true
that HCT treatment trials are not available for the
uninsured. Less obviously, clinical trials in HCT
may also be unavailable for the insured. Health in-
surers make determinations for coverage that vary
widely across and within plans. In a study by Peters
and Rogers [35], 533 women with stages II-IV breast
cancer were tracked for decisions on treatment cov-
erage for high-dose chemotherapy and autologous
HCT. Requests for coverage were denied in 121
(23%) of the women. In an accompanying editorial
in 1994, a call was made to bring fairness, rationality,
and public accountability to this reimbursement
process [36].
Fifteen years on, problems not only persist but, ar-
guably, are worse. Data from the first 95 patients with
severe SSc submitted for health insurance coverage for
the SCOT trial found that 51 (54%) subjects were ini-
tially denied coverage even though both treatments
had been published in top-tier, peer-reviewed journals
and found to have promising results [25,37]. Neverthe-
less, insurers judged the trial as ‘‘experimental or inves-
tigation’’ and denied coverage. Coverage decisions
varied widely both across and within plans and funding
Biol Blood Marrow Transplant 16:S48-S56, 2010 S55Hematopoietic Cell Transplantation for Autoimmune Diseasedecisions within the same company were inconsistent
or persistent in denial despite repeated prior reversals
of denial on outside independent review. As stated in
a recent Technology Assessment report prepared for
the Agency for Healthcare Research and Quality
(AHRQ), although published data are near nonexistent
to quantify the magnitude of the effect of third party
insurance denials on recruitment into clinical trials, in-
surance policies do restrict recruitment ontoNIH sup-
ported clinical studies, and thus impede clinical
research and the evidence needed to advance health
care of the nation [38].Research Opportunities
The irony is that as protocol development and re-
cruitment become more difficult and more laden with
processes, the opportunity for mechanistic and geno-
mic studies generated within clinical trials flourishes.
For allogeneic HCT, studies of non-HLA encoded
genes and their influence on outcomes is just begin-
ning. Genes controlling drug metabolism and immune
response are being discovered and will predict greater
individualization of treatment as biobanks of relevant
materials are being established worldwide [39]. Among
subjects funded by insurance and randomized on the
SCOT trial, over 4000 samples to date have been
stored at baseline and 10 time points after randomiza-
tion. Stored materials include serum, plasma, cells,
DNA, and RNA. Requests for proposal for scientific
studies using repository specimens were recently sent
to over 5100 rheumatologists and 180 medical school
directors of HCT programs and basic science depart-
ments in North America. In addition to the biobank,
the NIH has funded 9 additional mechanistic research
studies from materials from consenting subjects
enrolled in SCOT to determine the molecular mecha-
nisms of SSc, immune regulation, and responses to
treatment.CONCLUSIONS
Considerable advances have been gained in our un-
derstanding of the immunobiology of autoimmune
disease and HCT. Transient numeric depletion of im-
mune cells does not explain the prolonged remissions
observed after autologous HCT in patients with
autoimmune disorders. The sustained clinical effects
are better explained by qualitative change in the
reconstituted immune repertoire. Autologous HCT
induces substantial posttransplant modifications in
the adaptive immune system. It remains to be deter-
mined whether and to what extent the suppression of
inflammation observed posttherapy depends on the
eradication of disease-associated T and/or B cell pop-
ulations or on their regulation of function.Pilot clinical trials of HCT for autoimmune dis-
eases have paved the way for controlled RCTs that
are underway in Europe and the United States. These
studies illustrate the challenges of conducting clinical
treatment trials in an intense regulatory environment
found on both continents. Although impediments
from theU.S. health insurance system can restrict clin-
ical trial entry, there is vibrant opportunity and NIH
support of basic science investigations within pivotal
clinical trials.ACKNOWLEDGMENTS
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